

Niamh Coleman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5173875/publications.pdf>

Version: 2024-02-01

17
papers

242
citations

1307366

7
h-index

996849

15
g-index

17
all docs

17
docs citations

17
times ranked

438
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of circulating tumour cell clusters in human glioblastoma. <i>British Journal of Cancer</i> , 2018, 119, 487-491.	2.9	98
2	The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response. <i>British Journal of Cancer</i> , 2021, 124, 857-859.	2.9	26
3	Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib. <i>Lung Cancer</i> , 2019, 134, 117-120.	0.9	20
4	EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib. <i>Journal of Thoracic Oncology</i> , 2020, 15, e162-e165.	0.5	17
5	Targeting un-MET needs in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 164, 56-68.	0.9	15
6	Taking Aim at the Undruggable. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e145-e152.	1.8	14
7	CNS cancer immunity cycle and strategies to target this for glioblastoma. <i>Oncotarget</i> , 2018, 9, 22802-22816.	0.8	11
8	Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1517-1535.	0.4	9
9	Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring <i>MET</i> Exon 14 Skipping. <i>JCO Precision Oncology</i> , 2021, 5, 1802-1812.	1.5	9
10	Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience. <i>Journal of Neuro-Oncology</i> , 2018, 139, 107-116.	1.4	5
11	Where youth matters—clinicopathologic characteristics and emerging trends in treatment and outcomes in young Irish women with breast cancer. <i>Irish Journal of Medical Science</i> , 2019, 188, 59-67.	0.8	5
12	Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. <i>Clinical Medicine Insights: Oncology</i> , 2018, 12, 117955491875907.	0.6	4
13	Lorlatinib Salvages Central Nervous System—Only Relapse on Entrectinib in ROS1-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, e142-e144.	0.5	4
14	Safety, efficacy and survival of patients (pts) with primary CNS tumors in phase 1 (Ph1) trials: A 12-year single institution experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2043-2043.	0.8	2
15	Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. <i>Npj Precision Oncology</i> , 2021, 5, 99.	2.3	2
16	A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of daily oral BAL101553, a novel tumor checkpoint controller (TCC) in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS2601-TPS2601.	0.8	1
17	MGMT promoter methylation status: time for a frank discussion. <i>Journal of Neuro-Oncology</i> , 2017, 133, 667-668.	1.4	0